PE20120571A1 - Produccion de titulos elevados de polivirus para la produccion de vacunas - Google Patents

Produccion de titulos elevados de polivirus para la produccion de vacunas

Info

Publication number
PE20120571A1
PE20120571A1 PE2012000051A PE2012000051A PE20120571A1 PE 20120571 A1 PE20120571 A1 PE 20120571A1 PE 2012000051 A PE2012000051 A PE 2012000051A PE 2012000051 A PE2012000051 A PE 2012000051A PE 20120571 A1 PE20120571 A1 PE 20120571A1
Authority
PE
Peru
Prior art keywords
poliovirus
production
cells
polivirus
titles
Prior art date
Application number
PE2012000051A
Other languages
English (en)
Spanish (es)
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PE20120571A1 publication Critical patent/PE20120571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2012000051A 2009-07-16 2010-07-08 Produccion de titulos elevados de polivirus para la produccion de vacunas PE20120571A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16

Publications (1)

Publication Number Publication Date
PE20120571A1 true PE20120571A1 (es) 2012-06-06

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000051A PE20120571A1 (es) 2009-07-16 2010-07-08 Produccion de titulos elevados de polivirus para la produccion de vacunas

Country Status (32)

Country Link
US (4) US8546123B2 (sr)
EP (1) EP2454364B1 (sr)
JP (1) JP5845178B2 (sr)
KR (1) KR101548790B1 (sr)
CN (1) CN102482647B (sr)
AP (1) AP3140A (sr)
AR (1) AR077314A1 (sr)
AU (1) AU2010272685B2 (sr)
BR (1) BR112012000942B8 (sr)
CA (1) CA2763091C (sr)
CO (1) CO6491042A2 (sr)
CU (1) CU20120006A7 (sr)
DK (1) DK2454364T3 (sr)
EA (1) EA020563B1 (sr)
ES (1) ES2484093T3 (sr)
HR (1) HRP20140597T1 (sr)
IL (1) IL217465A (sr)
MA (1) MA33429B1 (sr)
MX (1) MX2011012648A (sr)
MY (1) MY183385A (sr)
NZ (1) NZ596880A (sr)
PE (1) PE20120571A1 (sr)
PL (1) PL2454364T3 (sr)
PT (1) PT2454364E (sr)
RS (1) RS53377B (sr)
SG (1) SG177655A1 (sr)
SI (1) SI2454364T1 (sr)
SM (1) SMT201400079B (sr)
TN (1) TN2011000628A1 (sr)
TW (1) TWI477606B (sr)
WO (1) WO2011006823A1 (sr)
ZA (1) ZA201108271B (sr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
AP3140A (en) 2009-07-16 2015-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
KR20150133695A (ko) * 2013-02-05 2015-11-30 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 제조를 위한 세포주 및 이의 사용 방법
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
EP2975119B1 (en) 2013-03-13 2020-03-11 ImmunoMax Co., Ltd. Cell strain having increased virus production ability and production method therefor
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
AU2015276235B2 (en) 2014-06-17 2021-02-18 Janssen Vaccines & Prevention B.V. Cold-Adapted-Viral-Attenuation (CAVA) and novel attenuated Poliovirus strains
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015294014B2 (en) * 2014-07-24 2018-08-23 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
EP3749757A4 (en) * 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US20220175908A1 (en) 2019-05-16 2022-06-09 Janssen Vaccines & Prevention B.V. Methods for Inducing a Safe Immune Response Against Polio Virus
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CN100383238C (zh) * 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
CA2557046A1 (en) 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
MX2007002372A (es) 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
AP3140A (en) 2009-07-16 2015-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
IL217465A (en) 2016-05-31
AR077314A1 (es) 2011-08-17
ZA201108271B (en) 2012-07-25
JP5845178B2 (ja) 2016-01-20
KR101548790B1 (ko) 2015-08-31
EP2454364B1 (en) 2014-04-23
US20110027317A1 (en) 2011-02-03
SI2454364T1 (sl) 2014-08-29
AP2012006075A0 (en) 2012-02-29
PT2454364E (pt) 2014-07-04
US20140242670A1 (en) 2014-08-28
US20130273106A1 (en) 2013-10-17
CA2763091C (en) 2019-07-23
TW201118173A (en) 2011-06-01
AU2010272685A1 (en) 2011-12-08
JP2012532616A (ja) 2012-12-20
DK2454364T3 (da) 2014-07-21
EA201270173A1 (ru) 2012-06-29
NZ596880A (en) 2013-10-25
EP2454364A1 (en) 2012-05-23
MA33429B1 (fr) 2012-07-03
US8546123B2 (en) 2013-10-01
TWI477606B (zh) 2015-03-21
US20130052224A1 (en) 2013-02-28
HK1164922A1 (en) 2012-09-28
PL2454364T3 (pl) 2014-09-30
CN102482647B (zh) 2015-12-16
RS53377B (sr) 2014-10-31
CA2763091A1 (en) 2011-01-20
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
WO2011006823A1 (en) 2011-01-20
TN2011000628A1 (en) 2013-05-24
US9022240B2 (en) 2015-05-05
SMT201400079B (it) 2014-09-08
CU20120006A7 (es) 2012-10-15
BR112012000942B8 (pt) 2021-05-25
SG177655A1 (en) 2012-02-28
MY183385A (en) 2021-02-18
IL217465A0 (en) 2012-02-29
HRP20140597T1 (hr) 2014-09-12
KR20120033334A (ko) 2012-04-06
AP3140A (en) 2015-02-28
EA020563B1 (ru) 2014-12-30
ES2484093T3 (es) 2014-08-11
BR112012000942A2 (pt) 2016-03-15
CN102482647A (zh) 2012-05-30
MX2011012648A (es) 2012-01-12
BR112012000942B1 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
PE20120571A1 (es) Produccion de titulos elevados de polivirus para la produccion de vacunas
MX362512B (es) Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MX2012002365A (es) Generación de lineas de linfocitos t citotóxicos con especificidad contra antígenos tumorales multiples o virus múltiples.
MX350966B (es) Celulas madre pluripotentes.
HN2011001446A (es) Compuesto utiles para inhibir chk1
CO6290704A2 (es) Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen.
UA112768C2 (uk) Європейський штам prrsv
AR068485A1 (es) Plantas con rendimiento incrementado
WO2014123967A3 (en) Cell lines for virus production and methods of use
WO2011133902A3 (en) Cell culture medium comprising small peptides
GB2449772A (en) Large scale production of stem cells
AR095354A1 (es) Métodos para el armado de bancos celulares de alta densidad
AR084715A1 (es) Fermentador para fermentar biomasa
AR097981A1 (es) Interferencia de la represión del factor de transcripción hd-zip de expresión génica para la producción de plantas con rasgos mejorados
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων
ES2351296B8 (es) Cepas de s. cerevisiae capaces de crecer en medios con melibiosa, estaquiosa y rafinosa.
JP2010166901A5 (sr)
CL2008003820A1 (es) Metodo para producir el virus de estomatitis vesicular atenuado (vsv) en un cultivo celular que comprende introducir en un vector el gen vsv g optimizado; composicion inmunogenica que comprende el vsv atenuado; kit para producir el vsv.
AR072150A1 (es) Metodo de replicacion del virus de la influenza en suspension
AR092688A1 (es) Metodos y composiciones para aumentar la resistencia a nematodos en plantas
AR112851A1 (es) Procedimiento para la obtención de una glicoproteína con un mayor porcentaje de glicanos afucosilados
AR056153A1 (es) Preparacion de estirpes celulars progenitoras para vacunas, usando cultivos de suspension de plantas biotecnologicas

Legal Events

Date Code Title Description
FG Grant, registration